var data={"title":"Iodixanol: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Iodixanol: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6385?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=iodixanol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Iodixanol: Patient drug information&quot;</a> and <a href=\"topic.htm?path=iodixanol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Iodixanol: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708949\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate use:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Not for intrathecal use. Inadvertent intrathecal administration may cause death, convulsions/seizures, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia, and brain edema.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183727\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Visipaque</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9746694\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Visipaque</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183730\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Iodinated Contrast Media;</li>\n      <li>\n        Radiological/Contrast Media (Nonionic, Iso-Osmolality)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2087667\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Angiocardiography (left ventriculography and selective coronary arteriography), cerebral arteriography, peripheral arteriography, visceral arteriography: </b>Intra-arterial: Iodixanol 320 mg iodine/mL: Dose individualized based on injection site and study type; refer to product labeling. Maximum recommended total dose of iodine: 80 g</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intra-arterial digital subtraction angiography:</b> Intra-arterial: Iodixanol 270 and 320 mg iodine/mL: Dose individualized based on injection site and study type; refer to product labeling. Maximum recommended total dose of iodine: 80 g</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CCTA, CT imaging of the head and body, excretory urography: </b>IV: Iodixanol 320 mg iodine /mL: Concentration and dose vary based on study type; refer to product labeling. Maximum recommended total dose of iodine: 80 g</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CT imaging of the head and body, excretory urography, peripheral venography: </b>IV: Iodixanol 270 mg iodine/mL: Concentration and dose vary based on study type; refer to product labeling. Maximum recommended total dose of iodine: 80 g</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2087666\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=iodixanol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Iodixanol: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Children &lt;12 years:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Angiocardiography, cerebral arteriography, visceral arteriography: </b>Intra-arterial: Iodixanol 320 mg iodine/mL: 1 to 2 mL/kg; maximum dose: 4 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>CT imaging of the head and body, excretory urography: </b>IV: Iodixanol 270 mg iodine /mL: 1 to 2 mL/kg; maximum dose: 2 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Children &ge;12 years and Adolescents: </b>Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2087668\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2087669\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Use caution in severe impairment and in setting of combined renal and hepatic disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Dialyzable (36% to 49% depending upon the membrane)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15962259\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. Use caution in patients with combined hepatic and renal disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183718\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Visipaque: 320 mg/mL (50 mL, 100 mL, 150 mL, 200 mL, 500 mL) [contains edetate calcium disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Visipaque: 270 mg/mL (50 mL, 100 mL, 150 mL, 200 mL) [pyrogen free; contains edetate calcium disodium, trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Visipaque: 320 mg/mL (50 mL) [pyrogen free; contains edetate calcium disodium]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183714\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2087670\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Patients should be adequately hydrated prior to and following administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid infiltration.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; initiate hyaluronidase antidote; elevate extremity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hyaluronidase:</i> Intradermal or SubQ: Inject a total of 1 mL (15 units/mL) as five separate 0.2 mL injections (using a 25-gauge needle) into area of extravasation at the leading edge in a clockwise manner (MacCara 1983; Zenk 1981) <b>or</b> injection of a total of 5 mL (150 units/mL) as five separate 1 mL injections around the extravasation site has been also used successfully (Rowlett 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183719\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intra-arterial:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Adults and pediatric patients &ge;12 years:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">270 and 320 mgI/mL: Intra-arterial digital subtraction angiography.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">320 mgI/mL: Angiocardiography (left ventriculography and selective coronary arteriography); cerebral arteriography; peripheral arteriography; visceral arteriography.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pediatric patients &lt;12 years: </i>320 mgI/mL: Angiocardiography; cerebral arteriography; visceral arteriography.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intravenous:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Adults and pediatric patients &ge;12 years:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">270 mgI/mL: Computed tomography (CT) imaging of the head and body; excretory urography; peripheral venography.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">320 mgI/mL: CT imaging of the head and body; excretory urography; coronary computed tomography angiography (CCTA) to assist in the diagnostic evaluation of patients with suspected coronary artery disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pediatric patients &lt;12 years:<b></b></i>270 mgI/mL: CT imaging of the head and body; excretory urography.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2087642\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">\n          <b>Not </b>for intrathecal use.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2087646\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Local: Discomfort at injection site (&le;30%), pain at injection site (&le;30%), warm sensation at injection site (&le;30%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Angina pectoris (&le;2%), chest pain (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (&le;3%), migraine (&le;3%), vertigo (2%), altered sense of smell (1%), paresthesia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (2%), erythema (&le;2%), skin rash (&le;2%; nonurticarial)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dysgeusia (4%), nausea (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Decreased thyroid hormones (transient; premature infants and infants with underlying medical conditions may be more vulnerable), hypothyroidism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acute renal failure, agitation, amnesia, anaphylactoid reaction, anaphylaxis, anxiety, apnea (children), asthma, atrioventricular block (children), back pain, bronchitis, bundle branch block (children), cardiac arrhythmia (children), cardiac failure (children), cerebrovascular disease, confusion, cortical blindness, diaphoresis, diarrhea, disseminated intravascular coagulation (children), dizziness, dyskinesia, dyspepsia, dyspnea, edema, fatigue, fever (children), flushing, hematoma, hematuria, hemorrhage, hypersensitivity reaction, hypertension, hypoesthesia, hypoglycemia, insomnia, malaise, nervousness, orthostatic hypotension, peripheral ischemia, pharyngeal edema, polymyalgia rheumatica, pulmonary edema, pulmonary embolism, renal function abnormality, respiratory depression, rhinitis, scotoma, seizure, sensory disturbance, shock, stupor, syncope, tinnitus, urticaria, visual disturbance, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183721\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intrathecal administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling</i>: Additional contraindications (not in US labeling): Hypersensitivity to iodixanol or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2087643\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contrast media reactions: Serious and life-threatening hypersensitivity reactions have occurred, including anaphylaxis. Use extreme caution with history of previous reaction to contrast dye, iodine-based contrast media or patients with a known clinical hypersensitivity (eg, bronchial asthma, hay fever, food allergies). Obtain allergy and hypersensitivity history prior to administration. Premedication with antihistamines or corticosteroids should be considered to reduce incidence and severity of reaction. Monitor closely during and for 30 to 60 minutes after administration (delayed reactions have occurred).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatological effects: Severe cutaneous adverse reactions (including Stevens-Johnson syndrome [SJS], toxic epidermal necrolysis [TEN], acute generalized exanthematous pustulosis [AGEP], drug reaction with eosinophilia and systemic symptoms [DRESS]) have occurred 1 hour to several weeks after administration; reaction severity may increase and time to onset may decrease with repeat administration. Avoid use in patients with a history of a severe cutaneous adverse reaction to iodixanol.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Vesicant; ensure proper needle/catheter/line placement prior to and during administration. Avoid extravasation, particularly in patients with severe arterial or venous disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal failure: Acute renal failure may occur; has been reported in patients with hepatic impairment administered an oral cholecystographic agent followed by an intravascular iodinated radiocontrast agent. Preparatory dehydration may contribute to acute renal failure in infants, young children and elderly patients, patients with preexisting renal impairment, multiple myeloma, advanced vascular disease, and diabetes; avoid fluid restriction and maintain normal hydration in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolic events: Serious, rarely fatal, thromboembolic events causing myocardial infarction and stroke have been reported during angiographic procedures with both ionic and nonionic contrast media. Use meticulous intravascular administration techniques, particularly during angiographic procedures. Ionic iodinated contrast media may inhibit blood coagulation (more than nonionic contrast media). Clotting has been reported when in vitro blood remains in contact with syringes containing nonionic contrast media; use of plastic syringes in place of glass syringes has been reported to decrease, but not eliminate, the likelihood of in vitro clotting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease and heart failure patients receiving concurrent diuretic therapy; they may have intravascular volume depletion, which may affect the renal response to the contrast agent osmotic load; observe such patients for several hours following the procedure to detect renal delayed hemodynamic renal function disturbances. Preparatory dehydration may contribute to acute renal failure in patients with advanced vascular disease; avoid fluid restriction and maintain normal hydration in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Preparatory dehydration may contribute to acute renal failure in patients with diabetes; avoid fluid restriction and maintain normal hydration in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment, and those with concomitant renal impairment, particularly when large doses are administered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Homocystinuria: Avoid angiography in patients with homocystinuria; may be at risk for thrombosis and embolism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperthyroidism: Thyroid storm following intravascular administration of iodinated contrast media have occurred in patients with hyperthyroidism or with an autonomously functioning thyroid nodule; use caution in severe thyrotoxicosis. Iodine-binding capacity of thyroid tissue may be reduced for at least 16 days following administration of contrast media for diagnosis of thyroid disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypothyroidism: Thyroid function tests indicative of hypothyroidism or transient thyroid suppression have been reported (uncommon) in adult and pediatric patients (including infants); some patients were treated for hypothyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple myeloma: Use with caution in patients with multiple myeloma or other paraproteinaceous diseases; use of intravascular contrast agents may lead to renal impairment, especially with concurrent dehydration. Partial dehydration in the preparation of these patients prior to injection is not recommended since this may predispose the patient to precipitation of the myeloma protein.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pheochromocytoma: Use with extreme caution in patients with pheochromocytoma (known or suspected). Dose injected should be kept to a minimum to minimize exposure; monitor blood pressure closely. Therapy to manage hypertensive crisis should be readily available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary disease: The risks of angiocardiography in patients with chronic pulmonary emphysema should be weighed against the necessity for the procedure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; combined renal and hepatic disease, combined renal and cardiac disease, or anuria; particularly when large doses are administered. Preparatory dehydration may contribute to acute renal failure in patients with preexisting renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sickle cell disease: Use with caution in patients with homozygous sickle cell disease; administration of contrast media may promote sickling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in elderly patients with age-related renal patients. Preparatory dehydration may contribute to acute renal failure in elderly patients; maintain adequate hydration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Children may have an increased risk of adverse effects, especially patients with asthma, sensitivity to allergens or medications, dehydration, heart failure, or serum creatinine &gt;1.5 mg/dL. Preparatory dehydration may contribute to acute renal failure in infants and young children.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate administration: For intravascular use only. <b>[US Boxed Warning]:</b> <b>Not for intrathecal use</b>. <b>Inadvertent intrathecal administration may cause death, convulsions/seizures, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia, and brain edema</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Adequately hydrate patient prior to and following administration. Delay intravenous contrast agent administration in patients who have recently received a cholecystographic contrast agent. In contrast-enhanced computerized tomography, contrast may obscure some lesions previously seen on unenhanced CT scans.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i> Intravascular administration:</i> In angiographic procedures, during catheter manipulations and contrast medium injection, a possibility of dislodging plaques or damaging (or perforating) vessel walls with resultant pseudoaneurysms, hemorrhage at puncture site, or dissection of coronary artery exists. Ensure proper catheter placement with test injections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Trained personnel: Clinicians using radiopaque contrast agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use during and for 30 to 60 minutes after administration (delayed reactions have occurred).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299528\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2087653\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8915&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: May enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetFORMIN: Iodinated Contrast Agents may enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis.  Management: Management advice varies. Refer to the full drug interaction monograph content for details.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183723\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. In general, iodinated contrast media agents may cross the placenta; use should be avoided unless absolutely required to obtain diagnostic information that will influence the care of the mother or fetus during pregnancy (ACOG 2016; ACR 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183724\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if iodixanol is present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Because of the low expected excretion of iodinated contrast agents into breast milk and the low absorption from an infant&rsquo;s GI tract, other sources note breastfeeding may be continued without interruption after use (ACOG 2016; ACR 2015). Theoretically, the taste of milk could be altered if it contains contrast media. Women who prefer to temporarily withhold breastfeeding can pump and store milk prior to the procedure and abstain from breastfeeding for 12 to 24 hours (ACR 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45684758\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;\">Monitor for signs/symptoms of hypersensitivity reactions for &ge;30 to 60 minutes; monitor for extravasation during IV administration; blood pressure; dehydration; renal function</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2087657\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Opacifies vessels in the path of flow permitting radiographic imaging of internal structures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2087659\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Note:</b> Following administration, the increase in tissue density is related to blood flow, the concentration of the iodixanol solution used, and the extraction of iodixanol by various interstitial tissues. The degree of enhancement is directly related to the iodine content in an administered dose. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Onset of action: Kidney:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Visualization: Renal parenchyma: 30 to 60 seconds; calyces and pelves (normal renal function): 1 to 3 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Optimum contrast: 5 to 15 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Distribution: V<sub>d</sub>: 0.26 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: No</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Metabolites have not been demonstrated</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric patients (Johnson 2001): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Newborns to Infants &lt;2 months: 4.1 &plusmn; 1.4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 2 to 6 months: 2.8 &plusmn; 0.6 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 6 to 12 months: 2.4 &plusmn; 0.4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 1 to &lt;3 years: 2.2 &plusmn; 0.5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 3 to &lt;12 years: 2.3 &plusmn; 0.5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 2.1 &plusmn; 0.1 hours; increased to 23 hours in renal impairment (mean CrCl: 13.61 &plusmn; 4.67 mL/minute)  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: IV: 0.75 to 1.25 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Immediate; peak enhancement at 15 to 120 seconds; optimum renal contrast at 5 to 15 minutes; brain contrast at up to 1 hour </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (97% within 24 hours); feces (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clearance: Adults: 110 mL/minute </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323201\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Visipaque Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">270 mg/mL (100 mL): $120.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">320 mg/mL (50 mL): $66.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038659\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Dixanol 270 (BD);</li>\n      <li>Dixanol 320 (BD);</li>\n      <li>Visipaque (AE, AT, AU, BE, BG, CH, CN, CO, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, HR, IE, IL, IS, JO, KR, KW, LK, LT, LU, LV, MT, NL, NO, PL, PT, QA, RU, SA, SE, SI, SK, TR, UY);</li>\n      <li>Vizypak (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice. Committee Opinion No. 656: guidelines for diagnostic imaging during pregnancy and lactation. <i>Obstet Gynecol</i>. 2016;127(2):e75-e80. doi:10.1097/AOG.0000000000001316.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iodixanol-drug-information/abstract-text/26942391/pubmed\" target=\"_blank\" id=\"26942391\">26942391</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Radiology Committee on Drugs and Contrast Media. ACR Manual on Contrast Media. Version 10.1. http://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/Contrast%20Manual/2015_Contrast_Media.pdf. Published 2015. Accessed April 15, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    FDA Safety Alert. MedWatch. Iodine-containing contrast agents for medical imaging. Food and Drug Administration website. Available at <a href=\"http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm472995.htm\" target=\"_blank\">http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm472995.htm</a>. Updated November 17, 2015. Accessed November 18, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jneid H, Anderson JL, Wright RS, et al, &ldquo;2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo; <i>Circulation</i>, 2012, 126(7):875-910.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iodixanol-drug-information/abstract-text/22800849/pubmed\" target=\"_blank\" id=\"22800849\">22800849</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson WH, Lloyd TR, Victorica BE, et al, &ldquo;Iodixanol Pharmacokinetics in Children,&rdquo; <i>Pediatr Cardiol</i>, 2001, 22(3):223-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iodixanol-drug-information/abstract-text/11343148/pubmed\" target=\"_blank\" id=\"11343148\">11343148</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klein LW, Sheldon MW, Brinker J, et al, &ldquo;The Use of Radiographic Contrast Media During PCI: A Focused Review: A Position Statement of the Society of Cardiovascular Angiography and Interventions,&rdquo; <i>Catheter Cardiovasc Interv</i>, 2009, 74(4):728-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iodixanol-drug-information/abstract-text/19830793/pubmed\" target=\"_blank\" id=\"19830793\">19830793</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Laskey WK, Jenkins C, Selzer F, et al, &ldquo;Volume-to-Creatinine Clearance Ratio: A Pharmacokinetically Based Risk Factor for Prediction of Early Creatinine Increase After Percutaneous Coronary Intervention,&rdquo; <i>J Am Coll Cardiol</i>, 2007, 50(7):584-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iodixanol-drug-information/abstract-text/17692741/pubmed\" target=\"_blank\" id=\"17692741\">17692741</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo; <i>Circulation</i>, 2011, 124(23):e574-651.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iodixanol-drug-information/abstract-text/22064601/pubmed\" target=\"_blank\" id=\"22064601\">22064601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacCara ME. Extravasation: a hazard of intravenous therapy. <i>Drug Intell Clin Pharm</i>. 1983;17(10):713-717.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iodixanol-drug-information/abstract-text/6628223/pubmed\" target=\"_blank\" id=\"6628223\">6628223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rowlett J. Extravasation of contrast media managed with recombinant human hyaluronidase. <i>Am J Emerg Med</i>. 2012;30(9):2102.e1-e3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iodixanol-drug-information/abstract-text/22633726/pubmed\" target=\"_blank\" id=\"22633726\">22633726</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Visipaque (iodixanol) [prescribing information]. Marlborough, MA: GE Healthcare Inc; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Visipaque (iodixanol) [product monograph]. Mississauga, Ontario, Canada: GE Healthcare Inc; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zenk KE. Management of intravenous extravasations. <i>Infusion</i>. 1981;5(4):77-79.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8915 Version 103.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708949\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F183727\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F9746694\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F183730\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F2087667\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F2087666\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F2087668\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F2087669\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15962259\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F183718\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F183714\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F2087670\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F183719\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F2087642\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F2087646\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F183721\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F2087643\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299528\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F2087653\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F183723\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F183724\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F45684758\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F2087657\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F2087659\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323201\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038659\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8915|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=iodixanol-patient-drug-information\" class=\"drug drug_patient\">Iodixanol: Patient drug information</a></li><li><a href=\"topic.htm?path=iodixanol-pediatric-drug-information\" class=\"drug drug_pediatric\">Iodixanol: Pediatric drug information</a></li></ul></div></div>","javascript":null}